BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Thyroid cancer AND NCOR2, SMRTE-tau, 9612, ENSG00000196498, SMRTE, TNRC14, TRAC-1, SMRT, CTG26, TRAC1 AND Treatment
18 results:

  • 1. TBL1X: At the crossroads of transcriptional and posttranscriptional regulation.
    Pray BA; Youssef Y; Alinari L
    Exp Hematol; 2022 Dec; 116():18-25. PubMed ID: 36206873
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. BRD4 inhibition and FXR activation, individually beneficial in cholestasis, are antagonistic in combination.
    Jung H; Chen J; Hu X; Sun H; Wu SY; Chiang CM; Kemper B; Chen LF; Kemper JK
    JCI Insight; 2020 Dec; 6(1):. PubMed ID: 33290278
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Histone deacetylase 3 indirectly modulates tubulin acetylation.
    Bacon T; Seiler C; Wolny M; Hughes R; Watson P; Schwabe J; Grigg R; Peckham M
    Biochem J; 2015 Dec; 472(3):367-77. PubMed ID: 26450925
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Cyclic AMP enhances progesterone action in human myometrial cells.
    Chen L; Lei K; Malawana J; Yulia A; Sooranna SR; Bennett PR; Liang Z; Grammatopoulos D; Johnson MR
    Mol Cell Endocrinol; 2014 Jan; 382(1):334-343. PubMed ID: 24161591
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Histone deacetylase turnover and recovery in sulforaphane-treated colon cancer cells: competing actions of 14-3-3 and Pin1 in HDAC3/smrt corepressor complex dissociation/reassembly.
    Rajendran P; Delage B; Dashwood WM; Yu TW; Wuth B; Williams DE; Ho E; Dashwood RH
    Mol Cancer; 2011 May; 10():68. PubMed ID: 21624135
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Formation of AR-smrt binding in prostate cancer cells treated with natural histone deacetylase inhibitor.
    Trtková K; Pašková L; Matiješčuková N; Kolář Z
    Cancer Biomark; 2010; 7(2):79-90. PubMed ID: 21178266
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Inhibition of MAP kinase promotes the recruitment of corepressor smrt by tamoxifen-bound estrogen receptor alpha and potentiates tamoxifen action in MCF-7 cells.
    Hong W; Chen L; Li J; Yao Z
    Biochem Biophys Res Commun; 2010 May; 396(2):299-303. PubMed ID: 20406620
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Inhibition of MAPK-signaling pathway promotes the interaction of the corepressor smrt with the human androgen receptor and mediates repression of prostate cancer cell growth in the presence of antiandrogens.
    Eisold M; Asim M; Eskelinen H; Linke T; Baniahmad A
    J Mol Endocrinol; 2009 May; 42(5):429-35. PubMed ID: 19223455
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Down-regulation of the tumor suppressor gene retinoic acid receptor beta2 through the phosphoinositide 3-kinase/Akt signaling pathway.
    Lefebvre B; Brand C; Flajollet S; Lefebvre P
    Mol Endocrinol; 2006 Sep; 20(9):2109-21. PubMed ID: 16613989
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Steroid hormone receptors and coregulators in endocrine-resistant and estrogen-independent breast cancer cells.
    Sarvilinna N; Eronen H; Miettinen S; Vienonen A; Ylikomi T
    Int J Cancer; 2006 Feb; 118(4):832-40. PubMed ID: 16152593
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Cell cycle progression stimulated by tamoxifen-bound estrogen receptor-alpha and promoter-specific effects in breast cancer cells deficient in N-CoR and smrt.
    Keeton EK; Brown M
    Mol Endocrinol; 2005 Jun; 19(6):1543-54. PubMed ID: 15802375
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Differential recruitment of coregulator proteins steroid receptor coactivator-1 and silencing mediator for retinoid and thyroid receptors to the estrogen receptor-estrogen response element by beta-estradiol and 4-hydroxytamoxifen in human breast cancer.
    Fleming FJ; Hill AD; McDermott EW; O'Higgins NJ; Young LS
    J Clin Endocrinol Metab; 2004 Jan; 89(1):375-83. PubMed ID: 14715875
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. p27(Kip1) induces quiescence and growth factor insensitivity in tamoxifen-treated breast cancer cells.
    Carroll JS; Lynch DK; Swarbrick A; Renoir JM; Sarcevic B; Daly RJ; Musgrove EA; Sutherland RL
    Cancer Res; 2003 Aug; 63(15):4322-6. PubMed ID: 12907598
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. The amino terminus of the human AR is target for corepressor action and antihormone agonism.
    Dotzlaw H; Moehren U; Mink S; Cato AC; Iñiguez Lluhí JA; Baniahmad A
    Mol Endocrinol; 2002 Apr; 16(4):661-73. PubMed ID: 11923464
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. The tamoxifen-responsive estrogen receptor alpha mutant D351Y shows reduced tamoxifen-dependent interaction with corepressor complexes.
    Yamamoto Y; Wada O; Suzawa M; Yogiashi Y; Yano T; Kato S; Yanagisawa J
    J Biol Chem; 2001 Nov; 276(46):42684-91. PubMed ID: 11553641
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Thyroxine promotes association of mitogen-activated protein kinase and nuclear thyroid hormone receptor (TR) and causes serine phosphorylation of TR.
    Davis PJ; Shih A; Lin HY; Martino LJ; Davis FB
    J Biol Chem; 2000 Dec; 275(48):38032-9. PubMed ID: 10982791
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Interactions of nuclear receptor coactivator/corepressor proteins with the aryl hydrocarbon receptor complex.
    Nguyen TA; Hoivik D; Lee JE; Safe S
    Arch Biochem Biophys; 1999 Jul; 367(2):250-7. PubMed ID: 10395741
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Evidence of a retinoid signaling alteration involving the activator protein 1 complex in tumorigenic human bronchial epithelial cells and non-small cell lung cancer cells.
    Lee HY; Dawson MI; Claret FX; Chen JD; Walsh GL; Hong WK; Kurie JM
    Cell Growth Differ; 1997 Mar; 8(3):283-91. PubMed ID: 9056670
    [TBL] [Abstract] [Full Text] [Related]  


    of 1.